Sort
39,280 grants matching “leukemia”
Microchimerism as AlloImmunity
$477,844J. Lee Lee Nelson · Fred Hutchinson Cancer Research Center · R01 · FY2016 · HL
Risk for Psychopathology and Neurocognitive Impairment in Leukemia Survivors
$477,814Kevin R Krull · St. Jude Children'S Research Hospital · R01 · FY2013 · MH
Designing T cells to Functionally Cure HIV-1 infection
$477,788James L Riley · University Of Pennsylvania · U19 · FY2018 · AI
HMGA Chromatin Remodeling Proteins in Tumor Progression in Myeloproliferative Neoplasms (MPN)
$477,782Linda M S Resar · Johns Hopkins University · R01 · FY2020 · HL
Control of B cell Development by YY1
$477,728Michael L. Atchison · University Of Pennsylvania · R01 · FY2020 · AI
Control of B cell Development by YY1
$477,728Michael L. Atchison · University Of Pennsylvania · R01 · FY2017 · AI
Control of B cell Development by YY1
$477,728Michael L. Atchison · University Of Pennsylvania · R01 · FY2018 · AI
Control of B cell Development by YY1
$477,728Michael L. Atchison · University Of Pennsylvania · R01 · FY2019 · AI
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
$477,726Michael Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia
$477,698Eric Padron · H. Lee Moffitt Cancer Ctr & Res Inst · R37 · FY2025 · CA
Cellular and molecular mechanisms of target tissue resistance for mitigating GVHD severity
$477,565Pavan Reddy · University Of Michigan At Ann Arbor · R01 · FY2017 · CA
Cellular and molecular mechanisms of target tissue resistance for mitigating GVHD severity
$477,565Pavan Reddy · University Of Michigan At Ann Arbor · R01 · FY2016 · CA
Cellular and molecular mechanisms of target tissue resistance for mitigating GVHD severity
$477,565Pavan Reddy · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Novel Epigenetic Approaches in AML
$477,555James E Bradner · Brigham And Women'S Hospital · P01 · FY2014 · CA
Exploring the potential of TET inhibition in cancer immunotherapy
$477,498Anjana Rao · La Jolla Institute For Immunology · R01 · FY2024 · CA
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
$477,479Yves A Declerck · Children'S Hospital Of Los Angeles · U54 · FY2014 · CA
MINORITY BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM
$477,478University Of Illinois At Chicago · U10 · FY2000 · CA
The pluripotency regulator Prdm14 initiates cancer by epigenetic mechanisms
$477,421Monica Jean Justice · Baylor College Of Medicine · R01 · FY2013 · CA
Structural And Functional Studies Of Human Swi/snf Chromatin-remodeling
$477,361Weidong Wang · National Institute On Aging · ZIA · FY2009 · AG
Mouse models of severe combined immunodeficiencies
$477,269Frederick W Alt · Beth Israel Deaconess Medical Center · P01 · FY2009 · AI
Murine gene knock-in models fo Omenn Syndrome and leaky SCID
$477,269Luigi Daniele Notarangelo · Beth Israel Deaconess Medical Center · P01 · FY2009 · AI
The function of PLZF in innate T cells
$477,250Derek B. Sant'angelo · Sloan-Kettering Inst Can Research · R01 · FY2010 · AI
MLL FUSION GENES IN MYELOID AND LYMPHOID LEUKEMIAS
$477,230Scott A Armstrong · Dana-Farber Cancer Inst · P01 · FY2012 · CA
In chronic myeloid leukemia, persistence of leukemia stem cells during tyrosine kinase inhibitor treatment is influenced by interaction with αβT cells
$477,218Elizabeth Ann Eklund · Northwestern University At Chicago · R01 · FY2025 · CA
Transcriptional regulatory landscapes underlying FEZ Formation
$477,213Ralph S Marcucio · University Of California, San Francisco · R01 · FY2020 · DE